查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1886301

生物相似药市场－全球产业规模、份额、趋势、机会和预测，依适应症、产品、地区和竞争格局划分，2020-2030年预测

Biosimilars Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球生物相似药市场规模将从2024年的310.7亿美元成长到2030年的423.6亿美元，年复合成长率为5.30%。生物相似药是与已核准的原厂生物药（即参考产品）高度相似的生物药品，在安全性、纯度和有效性方面均无临床意义上的差异。全球生物相似药市场成长的主要驱动因素是许多重磅生物药专利即将到期，促使人们寻求更经济实惠的替代疗法，以及全球慢性病盛行率的不断上升。

市场概览
预测期 2026-2030
市场规模：2024年 310.7亿美元
市场规模：2030年 423.6亿美元
复合年增长率：2025-2030年 5.30%
成长最快的细分市场 肿瘤学
最大的市场 北美洲

主要市场驱动因素

全球生物相似药市场扩张的根本驱动力在于许多高价值生物製剂的专利即将到期，这为更经济实惠的替代药物创造了巨大机会。製药业目前正面临2025年至2030年间高达2,360亿美元的专利悬崖，届时将有近70种重磅药物失去专利保护，并向生物相似药敞开大门，展开竞争。

主要市场挑战

生物相似药固有的生产复杂性和高昂成本严重阻碍了全球生物相似药市场的扩张。由于生物相似药复杂的生物学特性，其研发和生产需要大量的研发投入、高度专业化的生产设施以及严格的纯化製程。

主要市场趋势

全球生物相似药市场受到GLP-1受体激动剂生物相似药市场扩张的显着影响，这标誌着市场策略重点正转向高需求治疗领域。这一趋势旨在满足大量患有第2型糖尿病和肥胖症等慢性疾病的患者的需求，可望扩大药物可近性并降低医疗成本。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球生物相似药市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依适应症分类（肿瘤、发炎和自体免疫疾病、慢性疾病、血液疾病、生长激素缺乏症、传染病、其他）
    • 副产物（单株抗体、胰岛素、粒细胞集落刺激因子、红血球生成素、重组人类生长激素、依那西普、促卵泡素、特立帕肽、干扰素、抗凝血剂、其他）
    • 按地区
    • 按公司（2024 年）
  • 市场地图

第六章：北美生物相似药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲生物相似药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太生物相似药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲生物相似药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿联酋
    • 南非

第十章：南美洲生物相似药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章：市场动态

  • 司机
  • 挑战

第十二章：市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章：全球生物相似药市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商议价能力
  • 顾客的力量
  • 替代产品的威胁

第十五章：竞争格局

  • Dr. Reddy's Laboratories Ltd.
  • Sandoz Group AG
  • Coherus Biosciences
  • Viatris Inc.
  • Bio-Thera Solutions
  • Pfizer Inc.
  • Apobiologix
  • Teva Pharmaceuticals
  • Biocon Ltd
  • Reliance Life Sciences

第十六章：策略建议

第17章调查会社について・免责事项

简介目录
Product Code: 22689

The Global Biosimilars Market will grow from USD 31.07 Billion in 2024 to USD 42.36 Billion by 2030 at a 5.30% CAGR. Biosimilars are biological medical products highly similar to an already approved original biologic, known as the reference product, demonstrating no clinically meaningful differences in safety, purity, and effectiveness. The global biosimilars market's growth is primarily driven by the imminent patent expiry of numerous blockbuster biologics, compelling the demand for more affordable therapeutic alternatives, alongside the increasing prevalence of chronic diseases globally.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 31.07 Billion
Market Size 2030USD 42.36 Billion
CAGR 2025-20305.30%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

The global biosimilars market expansion is fundamentally propelled by the imminent patent expiration of numerous high-value biologic drugs, creating substantial opportunities for more affordable alternatives. The pharmaceutical industry is currently navigating a significant $236 billion patent cliff projected between 2025 and 2030, with nearly 70 blockbuster products set to lose exclusivity and open their therapeutic areas to biosimilar competition. This widespread loss of exclusivity acts as a primary catalyst, enabling biosimilar manufacturers to develop and launch products that directly compete with established biologics.

Key Market Challenges

The inherent manufacturing complexities and high associated costs represent a significant impediment to the global biosimilars market's expansion. Developing and producing biosimilar products requires extensive investment in research, highly specialized manufacturing facilities, and stringent purification processes due to their intricate biological nature. These factors directly contribute to extended development timelines and elevated capital expenditure for biosimilar manufacturers, creating substantial financial outlay and technical hurdles.

Key Market Trends

The global biosimilars market is significantly influenced by the expansion into GLP-1 agonist biosimilars, marking a strategic pivot towards high-demand therapeutic areas. This trend addresses the substantial patient populations grappling with chronic conditions such as type 2 diabetes and obesity, promising to broaden access and alleviate healthcare costs. The entry of biosimilar versions of these highly effective drugs is poised to intensify competition and foster innovation within this lucrative segment.

Key Market Players

  • Dr. Reddy's Laboratories Ltd.
  • Sandoz Group AG
  • Coherus Biosciences
  • Viatris Inc.
  • Bio-Thera Solutions
  • Pfizer Inc.
  • Apobiologix
  • Teva Pharmaceuticals
  • Biocon Ltd
  • Reliance Life Sciences

Report Scope:

In this report, the Global Biosimilars Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biosimilars Market, By Indication:

  • Oncology
  • Inflammatory and autoimmune diseases
  • Chronic diseases
  • Blood disorders
  • Growth hormone deficiency
  • Infectious diseases
  • Others

Biosimilars Market, By Product:

  • Monoclonal antibodies
  • Insulin
  • Granulocyte colony-stimulating factor
  • Erythropoietin
  • Recombinant human growth hormone
  • Etanercept
  • follitropin
  • Teriparatide
  • Interferons
  • Anticoagulants
  • Others

Biosimilars Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Biosimilars Market.

Available Customizations:

Global Biosimilars Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biosimilars Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Oncology, Inflammatory and autoimmune diseases, Chronic diseases, Blood disorders, Growth hormone deficiency, Infectious diseases, Others)
    • 5.2.2. By Product (Monoclonal antibodies, Insulin, Granulocyte colony-stimulating factor, Erythropoietin, Recombinant human growth hormone, Etanercept, follitropin, Teriparatide, Interferons, Anticoagulants, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Biosimilars Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biosimilars Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Biosimilars Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Biosimilars Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Product

7. Europe Biosimilars Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biosimilars Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product
    • 7.3.2. France Biosimilars Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Biosimilars Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Biosimilars Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Biosimilars Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Product

8. Asia Pacific Biosimilars Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biosimilars Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product
    • 8.3.2. India Biosimilars Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Biosimilars Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Biosimilars Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Biosimilars Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product

9. Middle East & Africa Biosimilars Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biosimilars Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Biosimilars Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Biosimilars Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product

10. South America Biosimilars Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biosimilars Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Biosimilars Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Biosimilars Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biosimilars Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dr. Reddy's Laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sandoz Group AG
  • 15.3. Coherus Biosciences
  • 15.4. Viatris Inc.
  • 15.5. Bio-Thera Solutions
  • 15.6. Pfizer Inc.
  • 15.7. Apobiologix
  • 15.8. Teva Pharmaceuticals
  • 15.9. Biocon Ltd
  • 15.10. Reliance Life Sciences

16. Strategic Recommendations

17. About Us & Disclaimer